Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography

Schiller, N. B., Shah, P. M., Crawford, M., DeMaria, A. N., Devereux, R. B., Feigenbaum, H., Gutgesell, H. P., Reichek, N., Sahn, D. J., Schnittger, I., et al. (1989) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(89)80014-8 · Cited by 8,110

Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year

Malmberg, K., Rydén, L., Efendic, S., Herlitz, J., Nicol, P., Waldenstrom, A., Wedel, H., & Welin, L. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00126-k · Cited by 1,560

Clinical Prevention of Sudden Cardiac Death by n-3 Polyunsaturated Fatty Acids and Mechanism of Prevention of Arrhythmias by n-3 Fish Oils

Leaf, A., Kang, J. X., Xiao, Y.-F., & Billman, G. E. (2003) · Circulation · doi:10.1161/01.cir.0000069566.78305.33 · Cited by 605

Glucagon-Like Peptides

Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 598

Metabolic Modulation of Acute Myocardial Infarction

Díaz, R., Paolasso, E., Piegas, L. S., Tajer, C. D., Moreno, M. G., Corvalán, R., Isea, J., Romero, G., & Collaborative Group (1998) · Circulation · doi:10.1161/01.cir.98.21.2227 · Cited by 517

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.

D'Alessio, D., Kahn, S., Leusner, C. R., & Ensinck, J. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117225 · Cited by 309

Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction

van der Horst, I. C. C., Zijlstra, F., Hof, A. W. J. V. ’., Doggen, C. J. M., de Boer, M., Suryapranata, H., Hoorntje, J. C. A., Dambrink, J. E., Gans, R. O. B., & Bilo, H. J. G. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00830-1 · Cited by 259

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

Ritzel, R. A., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 207

Insulin therapy as an adjunct toreperfusion after acute coronary ischemia

Sack, M. N., & Yellon, D. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00164-5 · Cited by 105

Glucose-Insulin-Potassium for Acute Myocardial Infarction

Apstein, C. S. (1998) · Circulation · doi:10.1161/01.cir.98.21.2223 · Cited by 95

New Investigational Drugs for the Management of Acute Heart Failure Syndromes

Tamargo, J. L., Amorós, I., Barana, A., Caballero, R., & Delpón, E. (2009) · Current Medicinal Chemistry · doi:10.2174/092986710790192721 · Cited by 17

Current Trends in Biomaterial Utilization for Cardiopulmonary System Regeneration

Fakoya, A. O. J., Otohinoyi, D. A., & Yusuf, J. A. (2018) · Stem Cells International · doi:10.1155/2018/3123961 · Cited by 17

Glucagon-like peptide-1 receptor expression after myocardial infarction: Imaging study using 68Ga-NODAGA-exendin-4 positron emission tomography

Ståhle, M. R., Kytö, V., Kiugel, M., Liljenbäck, H., Metsälä, O., Käkelä, M., Li, X., Oikonen, V., Saukko, P. J., Nuutila, P., et al. (2018) · Journal of Nuclear Cardiology · doi:10.1007/s12350-018-01547-1 · Cited by 17

Glucagon-like peptide 1 reverses myocardial hypertrophy through cAMP/PKA/RhoA/ROCK2 signaling

Fan, S., Xiong, Q., Zhang, X., Zhang, L., & Shi, Y. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa038 · Cited by 17

Incretin Therapies: Effects Beyond Glycemic Control

Mudaliar, S. R. D., & Henry, R. R. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.010 · Cited by 18

Serum Resistin: Physiology, Pathophysiology and Implications for Heart Failure

Bhalla, V., Kalogeropoulos, A. P., Georgiopoulou, V. V., & Butler, J. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.17 · Cited by 17

Glucagon-like peptide-1 receptor antagonism impairs basal exercise capacity and vascular adaptation to aerobic exercise training in rats

Scalzo, R. L., Knaub, L. A., Hull, S., Keller, A. C., Hunter, K. S., Walker, L. A., & Reusch, J. E. B. (2018) · Physiological Reports · doi:10.14814/phy2.13754 · Cited by 17

Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists

Gallwitz, B. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.247 · Cited by 17

Incretins: Clinical Physiology and Bariatric Surgery –Correlating the Entero-endocrine System and a Potentially Anti-dysmetabolic Procedure

Lamounier, R. N., Pareja, J. C., Tambascia, M. A., & Geloneze, B. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9098-y · Cited by 17

Exendin‐4 enhances radiation response of prostate cancer

He, W., & Li, J. (2018) · The Prostate · doi:10.1002/pros.23687 · Cited by 16

Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance

Cersosimo, A., Salerno, N., Sabatino, J., Scatteia, A., Bisaccia, G., Rosa, S. D., Dellegrottaglie, S., Bucciarelli‐Ducci, C., Torella, D., & Leo, I. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02181-7 · Cited by 17

The future: therapy of myocardial protection

Sanz‐Rosa, D., García‐Prieto, J., & Ibáñez, B. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06501.x · Cited by 16

Lixisenatide Treatment for Older Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetics: Meta-Analysis of Five Randomized Controlled Trials

Hanefeld, M., Berria, R., Lin, J., Aronson, R., Darmon, P., Evans, M., & Gaal, L. V. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0146-4 · Cited by 16

Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No

Madsbad, S. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.11.003 · Cited by 16

Dipeptidyl peptidase IV and Mortality After an Acute Heart Failure Episode

Lourenço, P., Friões, F., Silva, N., Guimarães, J. T., & Bettencourt, P. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3182949673 · Cited by 16

Cardiovascular protective properties of incretin-based therapies in type 2 diabetes

Şimşek, S., & de Galan, B. E. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283590b8f · Cited by 16

Exogenous Glucagon-Like Peptide-1 for Hyperglycemia in Critically Ill Patients

Pinelli, N. R., Jones, M. C., Monday, L., Smith, Z., & Rhoney, D. H. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q417 · Cited by 15

Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: A translational perspective for the cardiologist

Yin, M., Westenbrink, B. D., Meissner, M., van Gilst, W. H., & de Boer, R. A. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.10.005 · Cited by 16

Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes

Yabe, D., & Seino, Y. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.949672 · Cited by 16

Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus

Ryan, G. J., Moniri, N. H., & Smiley, D. D. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120168 · Cited by 17

The incretin system and cardiometabolic disease

Szmitko, P. E., Leiter, L. A., & Verma, S. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70010-6 · Cited by 17

Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction

Suman, R. K. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/15794.7459 · Cited by 16

Gastrointestinal factors regulating lipid droplet formation in the intestine

Auclair, N., Melbouci, L., St-Pierre, D., & Levy, E. H. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.12.031 · Cited by 16

Impact of Incretin Therapy on Islet Dysfunction: An Underlying Defect in the Pathophysiology of Type 2 Diabetes

McGill, J. B. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.01.1954 · Cited by 15

Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients

Karatoprak, C., Çakırca, M., Kanat, M., Çıkrıkçıoğlu, M. A., Sosyal, P., Hurşitoğlu, M., Camli, A. A., Erkoç, R., Kıskaç, M., Zorlu, M., et al. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s52545 · Cited by 15

Does Weight Loss Improve Clinical Outcomes in Overweight and Obese Patients with Heart Failure?

Tabucanon, T., Wilcox, J. D., & Tang, W. H. W. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01367-z · Cited by 16

Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited

Hansen, J., Brock, B., Bøtker, H. E., GJEDDE, A. H., Rungby, J., & Gejl, M. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9286-8 · Cited by 15

Incretins and the intensivist: what are they and what does an intensivist need to know about them?

Plummer, M. P., Chapman, M. J., Horowitz, M., & Deane, A. M. (2014) · Critical Care · doi:10.1186/cc13737 · Cited by 17

Inpatient Treatment of Type 2 Diabetes

Breuer, T. G. K., & Meier, J. J. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0466 · Cited by 14

Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study)

Htike, Z. Z., Yates, T. E., Brady, E. M., Webb, D. R., Gray, L. J., Swarbrick, D. J., McCann, G. P., Khunti, K., & Davies, M. J. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0421-6 · Cited by 16

Cardiac remodeling in obesity and after bariatric and metabolic surgery; is there a role for gastro-intestinal hormones?

Sanches, E. E., Timmermans, M., Topal, B., Çelik, A., Sundbom, M., Ribeiro, R. J. D. S., Parmar, C. D., Ugale, S. M., Proczko, M., Stepaniak, P. S., et al. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1690991 · Cited by 15

Review: DPP IV inhibitors - current evidence and future directions

Vilsbøll, T., & Knop, F. K. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070020401 · Cited by 16

Is the Way to Someone’s Heart Through Their Stomach?

Packer, M. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004551 · Cited by 15

Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure

Takahashi, A., Ihara, M., Yamazaki, S., Asanuma, H., Asakura, M., & Kitakaze, M. (2015) · International Heart Journal · doi:10.1536/ihj.15-028 · Cited by 14

Effect of sitagliptin treatment on metabolism and cardiac function in genetic diabetic mice

Hemmeryckx, B., Swinnen, M., Gallacher, D. J., Lu, H. R., & LIJNEN, H. R. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.12.036 · Cited by 14

Ranolazine triggers pharmacological preconditioning and postconditioning in anesthetized rabbits through activation of RISK pathway

Efentakis, P., Andreadou, I., Bibli, S.-I., Vasileiou, S., Dagres, N., Ζώγα, Α., Lougiakis, N., Kremastinos, D. T., & Iliodromitis, E. K. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.08.001 · Cited by 14

Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction

Hamad, F., Elnour, A. A., Abdelgadir, E., Mohamed, S., Yousif, I., Don, J., Beshir, S. A., Amoodi, A. A., Fathelrahman, A. I., Sam, K. G., et al. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816999200821164129 · Cited by 14

Incretin hormones and beta cell function in chronic pancreatitis.

Knop, F. K. (2010) · PubMed · Cited by 14

Conditioning the heart to prevent myocardial reperfusion injury during PPCI

Hausenloy, D. J. (2012) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872612438805 · Cited by 14

Potential cardioprotective action of GLP-1: from bench to bedside

Aronis, K. N., Tsoukas, M. A., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.009 · Cited by 14

Effects of HbA 1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide *

Paul, S. K., Best, J. D., Klein, K., Han, J., & Maggs, D. G. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01609.x · Cited by 14

Target therapies for radioiodine refractory advanced thyroid tumors.

Schlumberger, M. J. (2012) · PubMed · Cited by 14

Revisiting the Diabetes-Heart Failure Connection

Wallner, M., Eaton, D., von Lewinski, D., & Sourij, H. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1116-z · Cited by 14

Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications

Huri, H. Z., Hui, D. L. Y., & Ahmad, W. A. W. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s87294 · Cited by 14

Glycemic control and treatment patterns in patients with heart failure

Tang, W. H. W. (2007) · Current Cardiology Reports · doi:10.1007/bf02938357 · Cited by 13

New Treatments for Type 2 Diabetes: Cardiovascular Protection Beyond Glucose Lowering?

Jayawardene, D., Ward, G. M., O'Neal, D. N., Theverkalam, G., MacIsaac, A. I., & MacIsaac, R. J. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.05.007 · Cited by 13

Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus

Davidson, M. H. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2756 · Cited by 13

Stress hyperglycaemia in critically ill patients: potential role of incretin hormones; a preliminary study.

Llompart-Pou, J. A., Fernández-de-Castillo, A. G., Burguera, B. G., Pérez‐Bárcena, J., Marsé, P., Yago, M. Á. R., Barceló, A., & Raurich, J. M. (2012) · PubMed · doi:10.1590/s0212-16112012000100015 · Cited by 13

Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?

Strain, W. D., & Smith, C. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0165-z · Cited by 14

Non-Insulin Injectable Treatments (Glucagon-Like Peptide-1 and Its Analogs) and Cardiovascular Disease

Lebovitz, H. E., & Banerji, M. A. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0022 · Cited by 14

Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes

Wick, A., & Newlin, K. (2009) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2009.00455.x · Cited by 15

Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists?

Jax, T. W. (2008) · Clinical Research in Cardiology · doi:10.1007/s00392-008-0725-y · Cited by 13

Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto–Kakizaki rats

Wu, L., Olverling, A., Fransson, L., Ortsäter, H., Krizhanovskii, C., Gao, X., & Sjöholm, Å. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.05.091 · Cited by 13

Glucagon-Like Peptide-1 and its Cardiovascular Effects

Heo, K., Fujiwara, K., & Abe, J. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0265-9 · Cited by 13

Effects of glucagon-like peptide-1 agents on left ventricular function: Systematic review and meta-analysis

Liu, R., Li, L., Chen, Y., Yang, M., Liu, H., & Yang, G. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.949837 · Cited by 14

Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial

Kajiwara, M., Tanaka, A., Kawasaki, T., Nakao, K., Sakamoto, T., Toyoda, S., Inoue, T., Koga, N., & Node, K. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.10.009 · Cited by 13

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies

Schwartz, S. S. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s11389 · Cited by 16

Glucagon‐like peptide‐1 in type 2 diabetes: the β‐cell and beyond

Nauck, M. A. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00919.x · Cited by 13

Perioperative Use of GLP-1 Receptor Agonists in Patients Undergoing Cardiac Procedures: A Scoping Review

Wookey, O., Galligan, A., Wilkie, B. D., MacIsaac, A., & Paratz, E. D. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2024.11.025 · Cited by 12

Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes

Schwartz, S. S., DeFronzo, R. A., & Umpierrez, G. E. (2014) · Postgraduate Medicine · doi:10.1080/00325481.2015.996504 · Cited by 12

Reshaping Diabetes Care: The Fundamental Role of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Clinical Practice

Umpierrez, G. E., & Meneghini, L. (2013) · Endocrine Practice · doi:10.4158/ep12292.ra · Cited by 12

Cardiovascular Outcome Trials of the Incretin-Based Therapies: What Do We Know So Far?

Mora, P. F., & Johnson, E. L. (2016) · Endocrine Practice · doi:10.4158/ep161481.ra · Cited by 12

The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes

McHugh, K. R., DeVore, A. D., Mentz, R. J., Edmonston, D. L., Green, J. B., & Hernandez, A. F. (2018) · Clinical Cardiology · doi:10.1002/clc.23054 · Cited by 12

Implications of incretin-based therapies on cardiovascular disease

Rotz, M. E., Ganetsky, V. S., Sen, S., & Thomas, T. F. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12572 · Cited by 13

The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety

Green, J. B. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2566 · Cited by 12

Cell-based delivery of glucagon-like peptide-1 using encapsulated mesenchymal stem cells

Wallrapp, C., Thoenes, E., Thürmer, F., Jork, A., Kassem, M. S., & Geigle, P. (2012) · Journal of Microencapsulation · doi:10.3109/02652048.2012.726281 · Cited by 12

Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials

Wang, L., Xin, Q., Wang, Y., Chen, Z., Yuan, R., Yu, M., Zhang, G., & Cong, W. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105765 · Cited by 12

Taking lizard saliva to heart

Hausenloy, D. J., & Yellon, D. M. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr382 · Cited by 12

Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence

Seksaria, S., Dutta, B. J., Kaur, M., Gupta, G. D., Bodakhe, S. H., & Singh, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230809152148 · Cited by 12

Incretin-based therapy: a new horizon in diabetes management

Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 12

Glucagon-like peptide 1 receptor

Hoersch, D., Schrader, J., & Goeke, R. (2005) · AfCS-Nature Molecule Pages · doi:10.1038/mp.a001042.01 · Cited by 11

Management of the Patient With Diabetes and Coronary Artery Disease: A Contemporary Review

Raymond, T. E., Raymond, R. E., & Lincoff, A. M. (2013) · Future Cardiology · doi:10.2217/fca.13.22 · Cited by 11

Myocardial postconditioning: anaesthetic considerations.

Ortíz, P. L., Torres, J. C., Pastelı́n, G., & Rosas, M. (2011) · PubMed · Cited by 11

Liraglutide Activates Glucagon-Like Peptide 1 Receptor to Attenuate Hyperglycemia through Endogenous Beta-Endorphin in Diabetic Rats

Cheng, K., Li, Y., Shieh, P., Cheng, J., & Hsu, C.-C. (2020) · Pharmaceuticals · doi:10.3390/ph13110407 · Cited by 11

Maternal cardiovascular adaptation to pregnancy in women with previous bariatric surgery

Patel, D., Borrelli, N., Patey, O. V., Avesani, M., Johnson, M. R., Salvo, G. D., & Savvidou, M. D. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.08.052 · Cited by 11

Diabetes and the Cardiovascular System

McGuire, D. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00064-0 · Cited by 12

The 6th Annual World Congress on the Insulin Resistance Syndrome

Bloomgarden, Z. T. (2009) · Diabetes Care · doi:10.2337/dc09-zb09 · Cited by 11

Pharmacology of GLP-1-based therapies

Holst, J. J. (2008) · The British Journal of Diabetes · doi:10.1177/1474651408100523 · Cited by 11

Multidisciplinary combined treatment based on bariatric surgery for metabolic syndrome: a review article

Xie, J., & Wang, Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001320 · Cited by 10

Role of GLP‐1 Receptor Agonists in Managing Cancer Therapy–Related Cardiac Dysfunction

Vignarajah, A., Kim, S., Albliwi, M., Ahn, H. M., Izda, A., Naffa, F., Vigneswaramoorthy, N. A., Barot, S. V., & Shah, G. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.040919 · Cited by 10

Response of incretins (GIP and GLP-1) to an oral glucose load in female and male subjects with normal glucose tolerance

Matsuo, T., Kusunoki, Y., Katsuno, T., Ikawa, T., Akagami, T., Murai, K., Miuchi, M., Miyagawa, J., & Namba, M. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.09.002 · Cited by 10

Novel role for the incretins in blood pressure regulation

Yerram, P., & Whaley‐Connell, A. T. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328356bccd · Cited by 10

New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data

von Lewinski, D., Kolesnik, E., Wallner, M., Resl, M., & Sourij, H. (2017) · BioMed Research International · doi:10.1155/2017/1253425 · Cited by 10

Cardiovascular effects of antiobesity drugs: are the new medicines all the same?

Cataldi, M., Cignarelli, A., Giallauria, F., Muscogiuri, G., Barrea, L., Savastano, S., & Colao, A. A. L. (2020) · International Journal of Obesity Supplements · doi:10.1038/s41367-020-0015-3 · Cited by 11

Cardioprotective Actions of a Glucagon‐like Peptide‐1 Receptor Agonist on Hearts Donated After Circulatory Death

Kadowaki, S., Siraj, M. A., Chen, W., Wang, J., Parker, M., Nagy, A., Fan, C. S., Runeckles, K., Li, J., Kobayashi, J., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027163 · Cited by 10

Admission Glucose and Risk of Early Death in Non-Diabetic Patients with ST-Segment Elevation Myocardial Infarction: A Meta-Analysis

Liu, Y. (2015) · Medical Science Monitor · doi:10.12659/msm.894249 · Cited by 10

Roux-en-Y gastric bypass attenuates the progression of cardiometabolic complications in obese diabetic rats via alteration in gastrointestinal hormones

Lau, R. G., Kumar, S., Hall, C. E., Palaia, T. A., Rideout, D. A., Hall, K. N., BRATHWAITE, C. E. M., & Ragolia, L. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.12.005 · Cited by 10

DPP-4 inhibitors and atherosclerosis: The promise

Jialal, I., & Bajaj, M. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.12.033 · Cited by 10

Effect of food intake on left ventricular wall stress

Gårdinger, Y., Hlebowicz, J., Björgell, O., & Dencker, M. (2014) · Cardiovascular Ultrasound · doi:10.1186/1476-7120-12-2 · Cited by 10

Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease

Sanchez, R. A., Sanabria, H. D., Santos, C. D. L., & Ramirez, A. J. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i11.1186 · Cited by 10

The role of glucagon‑like peptide 1 in glucose homeostasis and in other aspects of human physiology

Franek, E., Gajos, G., Gumprecht, J., Kretowski, A. J., Zahorska‐Markiewicz, B., & Malecki, M. T. (2009) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.829 · Cited by 11

HSP90-Mediates Liraglutide Preconditioning-Induced Cardioprotection by Inhibiting C5a and NF-κB

He, S., Wang, D., Meng, J., Cheng, X., Bi, Q., Zhong, G., & Tu, R. (2021) · Journal of Investigative Surgery · doi:10.1080/08941939.2021.1989729 · Cited by 10

Incretin attenuates diabetes-induced damage in rat cardiac tissue

Elbassuoni, E. (2014) · The Journal of Physiological Sciences · doi:10.1007/s12576-014-0327-6 · Cited by 10

Effect of peripherally-injected glucagon-like peptide-1 on gastric mucosal blood flow

Işbil-Büyükcoşkun, N., Çam-Etöz, B., Süyen, G. G., & Özlük, K. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.04.013 · Cited by 10

Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications

Giorgino, F., Natalicchio, A., Leonardini, A., & Laviola, L. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.09.022 · Cited by 10

Effects of glucagon-like peptide 1 analogs in combination with insulin on myocardial infarct size in rats with type 2 diabetes mellitus

Зыков, В. А., Тучина, Т. П., Лебедев, Д. А., Борисовна, К. И., Babenko, A. Y., Кулешова, Э. В., Grineva, E. N., Азизович, Б. А., & Galagudza, M. M. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i9.149 · Cited by 10

Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide

Odigwe, C. I., Mulyala, R. R., Malik, H., Ruiz, B., Riad, M., Sayiadeh, M. A., Honganur, S., Parks, A., Rahman, M. U., & Lakkis, N. M. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100518 · Cited by 9

The Potential Role of GLP1-RAs Against Anticancer-Drug Cardiotoxicity: A Scoping Review

Biondi, F., & Madonna, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082705 · Cited by 11

GLP-1 activates KATP channels in coronary pericytes as the effector of brain-gut-heart signalling mediating cardioprotection

Mastitskaya, S., Freitas, F., Evans, L., & Attwell, D. (2026) · Nature Communications · doi:10.1038/s41467-026-69555-1 · Cited by 9

Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials

Huang, M., Wei, R., Wang, Y., Su, T.-Y., Li, Q., Yang, X., & Chen, X. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1306653 · Cited by 35

GLP-1 Infusions in the setting of Acute Myocardial Infarction Improve Myocardial Function and Reduce Morbidity and Mortality

Bush, G. J. (2013)

Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

Read, P. A., Khan, F. Z., & Dutka, D. P. (2011) · Heart · doi:10.1136/hrt.2010.219345 · Cited by 114

Role of glucagon-like peptide-1 agonist in patients undergoing percutaneous coronary intervention or coronary artery bypass grafting: A meta-analysis

Ogbu, I. R., Ngwudike, C., Lal, K., Danielian, A., & Daoud, S. N. (2021) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2021.100063 · Cited by 4

Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus

McCormick, L. M., Heck, P. M., Ring, L. S., Kydd, A. C., Clarke, S. J., Hoole, S. P., & Dutka, D. P. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0259-3 · Cited by 23